22nd Century Group (XXII) Updates Second Quarter 2023 Results Webcast Time on August 14, 2023
09 August 2023 - 2:00PM
22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology
company dedicated to improving health with reduced nicotine
tobacco, hemp/cannabis and hops advanced plant technologies, will
host a live webcast on Monday, August 14, 2023, at a revised time
of 8:00 AM ET to discuss its 2023 second quarter results, which are
to be reported in a press release at 6:00 AM ET the same day.
During the webcast, John Miller, interim chief executive
officer, and Hugh Kinsman, chief financial officer, will review
financial results and discuss progress made in each of the
Company’s three franchises.
Following management’s prepared remarks and slide presentation,
the Company will host a Q&A session, during which management
will accept questions from research analysts.
The live and archived webcast and slide presentation will be
accessible on the Events web page in the Company's Investor
Relations section of the website, at
https://ir.xxiicentury.com/events-and-presentations/default.aspx.
Please access the website at least 15 minutes prior to the start of
the webcast to register and, if necessary, download and install any
required software.
About 22nd Century Group,
Inc.22nd Century Group, Inc. (Nasdaq: XXII) is a
leading agricultural biotechnology company focused on tobacco harm
reduction, reduced nicotine tobacco and improving health and
wellness through plant science. With dozens of patents allowing it
to control nicotine biosynthesis in the tobacco plant, the Company
has developed proprietary reduced nicotine content (RNC) tobacco
plants and cigarettes, which have become the cornerstone of
the FDA’s Comprehensive Plan to address the widespread
death and disease caused by smoking. The Company received the first
and only FDA Modified Risk Tobacco Product (MRTP) authorization of
a combustible cigarette in December 2021. In tobacco, hemp/cannabis
and hop plants, 22nd Century uses modern plant breeding
technologies, including genetic engineering, gene-editing, and
molecular breeding to deliver solutions for the life science and
consumer products industries by creating new, proprietary plants
with optimized alkaloid and flavonoid profiles as well as improved
yields and valuable agronomic traits.
Learn more at xxiicentury.com, on Twitter,
on LinkedIn, and on YouTube.
Learn more about
VLN® at tryvln.com.
Cautionary Note Regarding Forward-Looking
StatementsExcept for historical information, all of the
statements, expectations, and assumptions contained in this press
release are forward-looking statements. Forward-looking statements
typically contain terms such as “anticipate,” “believe,”
“consider,” “continue,” “could,” “estimate,” “expect,” “explore,”
“foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,”
“potential,” “predict,” “preliminary,” “probable,” “project,”
“promising,” “seek,” “should,” “will,” “would,” and similar
expressions. Actual results might differ materially from those
explicit or implicit in forward-looking statements. Important
factors that could cause actual results to differ materially are
set forth in “Risk Factors” in the Company’s Annual Report on Form
10-K filed on March 9, 2023. All information provided in this
release is as of the date hereof, and the Company assumes no
obligation to and does not intend to update these forward-looking
statements, except as required by law.
Investor Relations & Media ContactMatt
KrepsInvestor Relations22nd Century
Groupmkreps@xxiicentury.com214-597-8200
22nd Century (NASDAQ:XXII)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
22nd Century (NASDAQ:XXII)
Historical Stock Chart
Von Jun 2023 bis Jun 2024